Biotech Calendar: Key Dates for April

BOSTON (TheStreet) -- A calendar of important, potentially stock-moving biotech events for April:

April 7

The U.S. Food and Drug Administration convenes an advisory panel to discuss Forest Labs'(FRX) Daxas for chronic obstruction pulmonary disease. The FDA's briefing documents should be posted to the agency's web site on April 5.

April 8

Celgene(CELG) analyst/investor day.
Lexicon Pharmaceuticals(LXRX) analyst/investor day.

April 9

Cell Therapeutics(CTIC) annual shareholders meeting.

April 10-17

American Academy of Neurology annual meeting. Data presentations expected from Genzyme(GENZ), Acadia Pharmaceuticals(ACAD) and Acorda Therapeutics(ACOR), among others.

April 13-17

AMAG Pharmaceuticals(AMAG) presents Feraheme data at National Kidney Foundation meeting.

April 14-18

European Association for the Study of the Liver (EASL) annual meeting. Hepatitis C data expected from Vertex Pharmaceuticals(VRTX), Idenix Pharmaceuticals(IDIX), Pharmasset(VRUS) and Anadys(ANDS), among others.

April 17-21

American Association for Cancer Research annual meeting. Data presentations expected from Cyclacel Pharmaceuticals(CYCC), Dendreon(DNDN) and Peregrine Pharmaceuticals(PPHM), among others.

April 18

FDA approval decision date for OSI Pharmaceuticals'(OSIP) Tarceva in first-line non-small cell lung cancer.

April 22

FDA convenes advisory panel to review Acura Pharmaceuticals'(ACUR) abuse-resistant pain drug Acurox.

April 23

FDA approval decision date for Cell Therapeutics' pixantrone for non-Hodgkin's lymphoma.

April 30

FDA approval decision date for Pozen's(POZN) pain drug Vimovo.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

>To order reprints of this article, click here: Reprints